Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirtris Pharmaceuticals has said that company's co-founder David Sinclair will present positive data showing that SIRT1 activation can suppress tumor formation and growth in the intestine and colon in a preclinical model of colon cancer.
Subscribe to our email newsletter
These are assumed to be the first in-vivo data showing that SIRT1 overexpression can suppress tumor formation and growth. These data are the work of Sirtris scientific advisory board co-chairs Sinclair and Leonard Guarente, the Novartis professor of biology at the Massachusetts Institute of Technology.